Toxic Tort Mistakes That Leave Enterprise Reserves Too Low

A toxic tort is a lawsuit filed by a person alleging that a substance has harmed them in a certain way. The substance might include chemicals, minerals, drug compounds, and building materials.

Most risk teams assess these claims with the same tools they use for ordinary product complaints, which is where the trouble starts. What sets toxic torts apart from other product cases is that the illness may develop after 30 to 40 years, which is something you quite often see in cases involving asbestos exposure. Here are some of the most common mistakes they make.

Mistake 1: Counting Cases, Not Reading the Structure

When the lawsuits start arriving, the natural assumption is that each one gets fought on its own, with its own evidence, its own judge, and its own settlement. But that’s not the case when the courts group them together.

Federal judges consolidate similar lawsuits under a single judge in what is called multidistrict litigation, or MDL. Each case remains legally separate, so the company can’t lose everything in a single verdict. However, gathering evidence occurs once and covers everything, which means a single document found in one case becomes available to every lawyer in the group.

That lawyer’s group can be enormous. For instance, the federal MDL covering Johnson and Johnson and mesothelioma claims and related cancers held 67,204 pending cases in the official court count. Each of those cases carries its own price tag, and juries in the state trials so far have awarded amounts ranging from a few million dollars to hundreds of millions. Multiply one damaging document across that many claims and the arithmetic turns ugly quickly.

Trust funds work the other way around. A court approves a fixed sum, sets it aside, and pays claimants on a published schedule. The talc defendant proposed precisely that, offering $9 billion through a subsidiary to close out its ovarian cancer claims.

The difference matters for your reporting. An MDL leaves the exposure open-ended and growing, and a trust turns it into a fixed figure for the balance sheet. Therefore, it’s important to ask your legal team which of the two your claims are heading toward so you can plan accordingly.

Mistake 2: Treating Bankruptcy as a Cap

Some companies move their toxic tort liability into a small subsidiary, then file for bankruptcy to limit what claimants can recover, but judges have grown tired of the tactic. A court rejected one such filing in 2023 on the grounds that it improperly shielded a solvent company, and a Texas judge dismissed the third attempt in March 2025.

You should treat these structures as a possibility and never as a cap. A failed attempt costs legal fees, several years and credibility with the court that will hear the case afterwards, so your reserve has to hold even when the structure does not.

Mistake 3: Assuming the Old Insurance Will Respond

Companies often count their old insurance as an offset in the reserve paperwork before anybody has confirmed it exists. Policies from the 1960s and 1970s may pay out for exposure from those years, but tracing them means finding paperwork that predates most document systems.

Insurers also routinely dispute these claims, arguing over which policy year applies and how the damage should be split between them. It’s vital to confirm the cover exists before anyone books it as an offset. Finance teams that skip that step tend to revise the number at an awkward moment, often in front of the board.

Endnote

A toxic tort reserve set last year is almost certainly too small today, as claim counts keep climbing and each new verdict raises the value of the remaining cases. Companies that handle this well give the board a realistic number early and update it as cases progress. Doing so leaves you room to negotiate, time to settle on reasonable terms, and a clear answer when investors ask what you knew. Remember, the litigation and the verdicts are outside your hands, but the timing of an honest disclosure is not.